fbpx

News

Lundbeckfonden Ventures News

Expands focus on gram-negative bacteria by adding Potentiator program to pipeline of novel antibiotic compounds.CAMBRIDGE, Mass.- June 8, 2015 -  Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced that the company secured $30M million in a Series A financing.  Lundbeckfond Ventures led the round as a...
Pivotal Rat Study Presented at 2015 Orthopedic Research Society Annual Meeting  Lund, Sweden, (PRNEWSWIRE) May 27, 2015 - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced results from a pivotal pre-clinical study of CERAMENTT'G as presented at the 2015 Orthopedic Research Society...
South San Francisco, CA - May 12, 2015 - Iconic Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor biology to new therapeutics for retinal disease and cancer, today announced that K. Peter Hirth, PhD, co-founder and formerly Chief Executive Officer of Plexxikon, Inc., has been named a Director...
OXFORD, UK - 19 May 2015 - PsiOxus Therapeutics Ltd. (PsiOxus), the oncolytic immuno-oncology company, has closed a Series C financing round of £25 million (c$38.5 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes from the antibody 'armed' series of AbEnAd viruses.
Lund, Sweden, (PRNEWSWIRE) May 13, 2015 - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received the Frost & Sullivan 2015 Growth Capital Investment Award for outstanding achievement and superior performance in the area of technological innovation and strategic product development in...
Primary endpoint of preventing delayed CINV met with high significanceCambridge, UK - 6th May 2015: Acacia Pharma Ltd (Acacia Pharma" or "the Company"), a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention...
Lund, Sweden, (PRNEWSWIRE) April 29, 2015 - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received CE-mark for CERAMENTT'V, the first injectable vancomycin eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis.  CERAMENTT'V...
Novel formulation and proprietary patch pump would offer a new and different option for the management of fluid overload in heart failure.
Cambridge, UK - 21st April 2015: Acacia Pharma Ltd (Acacia Pharma" or "the Company"), the supportive care company developing  products for US and international markets, announces the initiation of a Phase 3 study investigating APD421 in combination with standard antiemetics, in the prevention of post-operative nausea & vomiting (PONV) in high-risk patients. PONV remains a...
1 41 42 43 44 45 64

Lundbeckfonden Ventures

News

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
3. April 2020
Acacia Pharma Group PLC – Publication of Prospectus
25. March 2020
Acacia Pharma Group PLC – Forthcoming 2020 Annual General Meeting – Change of Venue and Proxy Forms
23. March 2020